Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

de Aguirre; Patricia Boya; Daniel Bellet; Sandrine Faivre; Frédéric Troalen; Jean Bénard; Patrick Saulnier; Sally Hopkins-Donaldson; Uwe Zangemeister‐Wittke; Guido Guido Kroemer; Éric Raymond

doi:10.1023/b:appt.0000045781.46314.e2

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article1998

Effects of 2-Chlorodeoxyadenosine and Gold Sodium Thiomalate on Human bcl-2 Gene Expression

P. Sfikakis, Meletios A Dimopoulos, V.L. Souliotis, D. Charalambopoulos, Myron Mavrikakis, Panayiotis Panayiotidis

Article2007

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

Liqing Zhuang, C Soon Lee, Richard A Scolyer, Stanley W. McCarthy, Xu Dong Zhang, John F. Thompson, Peter Hersey

Article2000

Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma

Antonio Sica, Alessandra Saccani, Barbara Bottazzi, Sergio Bernasconi, Paola Allavena, Brancatelli Gaetano, Francesca Fei, Graig LaRosa, Chris J. Scotton, Frances R. Balkwill, Alberto Mantovani

Article1999

Prognostic Significance of p53, bcl-2 and EGFR in Carcinoma of the Endometrium

Pauline Athanassiadou, E. Petrakakou, Anna Liossi, Lydia Nakopoulou, Cherry Zerva, Meletios A Dimopoulos, P. Athanassiades

Article2006

Increased expression of Mcl-1 and Bcl-XL and decreased expression of Bcl-2 associated with melanoma progression and transcription factors

L. Zhuang, C. Lee, Richard A Scolyer, Susan McCarthy, X. Zhang, James A. Thompson, Peter Hersey